Oculis (NASDAQ:OCS) Price Target Lowered to $28.00 at HC Wainwright

Oculis (NASDAQ:OCS) had its price target reduced by equities research analysts at HC Wainwright from $29.00 to $28.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 133.92% from the stock’s current price.

OCS has been the subject of several other reports. Robert W. Baird decreased their price target on shares of Oculis from $64.00 to $35.00 and set an “outperform” rating for the company in a research note on Tuesday, March 19th. Chardan Capital reiterated a “buy” rating and issued a $30.00 price target on shares of Oculis in a research note on Tuesday, March 19th. Finally, Wedbush restated an “outperform” rating and set a $29.00 price objective on shares of Oculis in a research note on Wednesday, March 6th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Oculis has an average rating of “Buy” and a consensus price target of $29.14.

Oculis Stock Up 0.2 %

NASDAQ:OCS opened at $11.97 on Wednesday. The company has a 50-day moving average price of $11.90 and a 200-day moving average price of $11.22. Oculis has a 12 month low of $9.05 and a 12 month high of $14.50. The company has a quick ratio of 5.29, a current ratio of 5.29 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last posted its earnings results on Monday, March 18th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.04. The company had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.28 million. On average, research analysts expect that Oculis will post -1.75 earnings per share for the current year.

Institutional Trading of Oculis

A number of large investors have recently made changes to their positions in the stock. Barclays PLC purchased a new position in shares of Oculis in the second quarter worth approximately $44,000. Wolverine Asset Management LLC purchased a new position in shares of Oculis in the third quarter worth approximately $77,000. Searle & CO. purchased a new position in shares of Oculis in the fourth quarter worth approximately $112,000. Compagnie Lombard Odier SCmA boosted its holdings in shares of Oculis by 47.3% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock worth $1,053,000 after buying an additional 30,750 shares during the last quarter. Finally, abrdn plc purchased a new position in shares of Oculis in the fourth quarter worth approximately $15,980,000. 22.30% of the stock is currently owned by institutional investors.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.